Tazarotene 0.1% gel in combination with mometasone furoate cream in plaquepsoriasis: A photographic tracking study

A photographic tracking study was performed to facilitate a visual evaluati on of the effect of treating psoriatic lesions in a clinical setting with t azarotene 0.05% gel, tazarotene 0.1% gel, tazarotene 0.1% gel plus mometaso ne furoate as needed for irritation, or tazarotene 0.1% gel plus mometasone furoate, Tazarotene was administered once daily in the evening, and mometa sone furoate was administered once daily in the morning, for 12 weeks or un til clearance if this occurred first. A total of twenty patients were enrol led in this open-label study. Rates of treatment success (50% or greater im provement in psoriasis) were higher with tazarotene 0.1% monotherapy compar ed with tazarotene 0.05% monotherapy, and were higher still when tazarotene was used in combination with mometasone furoate. Concurrent use of this st eroid also enhanced speed of efficacy, patient satisfaction, and tolerabili ty, Furthermore, long periods of remission were achieved in patients treate d with combination tazarotene plus corticosteroid therapy These findings su ggest that tazarotene plus a mid-potency topical corticosteroid is a valuab le first-line treatment option for stable plaque psoriasis.